Dr. Bekaii-Saab is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5881 E. Mayo Boulevard
Phoenix, AZ 85050
Summary
- Tanios Bekaii-Saab is a Professor of Medicine at the Mayo Clinic College of Medicine and Science, Leader of the Gastrointestinal Cancer Program at the Mayo Clinic Cancer Center, Chair Medical Oncology and Hematology in at the Mayo Clinic in Phoenix, Arizona, USA. He is also the consortium chair for the ACCRU research Network. Dr. Bekaii-Saab earned his medical degree from the American University of Beirut and completed a residency in internal medicine at Indiana University. He then completed fellowships in clinical pharmacology/experimental therapeutics and oncology at Tufts University/New England Medical Center in Boston.
Dr. Bekaii-Saab, MD, conducts clinical/translational research focused on developing anticancer agents for patients with gastrointestinal cancers. Dr. Bekaii-Saab collaborates with various scientists and industry partners to design and execute innovative clinical trials, including many first-in-human studies. Bekaii-Saab’s research includes a focus on the incorporation of agents that target the multiple facets of cancer, including genetic drivers, as well as the microenvironment and the immune milieu. His work includes 2 recent discoveries as coinventor of a molecule that targets cancer-related cachexia (AR-42) and an anti–PD-1 vaccine. His research has led to the launch of a number of phase II and III clinical trials, including a recent trial with a cancer stem cell inhibitor (napabucasin) in pancreatic cancer, the development of an FGFR inhibitor in bile duct cancers, and a contribution to the pivotal study that led to the regulatory approval of nanoliposomal irinotecan for treating pancreatic cancer.
Dr. Bekaii-Saab has authored or co-authored more than 500 peer reviewed publications, abstracts, and book chapters, including papers in Lancet Oncology, Journal of Clinical Oncology, JAMA, Journal of the National Cancer Institute, Annals of Oncology, and Clinical Cancer Research.
Education & Training
- Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
- Indiana University School of MedicineResidency, Internal Medicine, 1996 - 1999
- American University of Beirut Faculty of MedicineClass of 1996
- McGill UniversityB.S., Neuro Biology, With Great Distinction, 1990 - 1992
- American University of BeirutNo Degree, Dean's Honor List, 1987 - 1989
Certifications & Licensure
- AZ State Medical License 2015 - 2025
- OH State Medical License 2002 - 2017
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- High Performing Physician 2013
- Best Doctor Best Doctors in America, 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer Start of enrollment: 2005 Oct 01
- 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery Start of enrollment: 2006 Dec 20
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2006 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 33 citationsTemporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.Milind Javle, Sunyoung Lee, Nilofer S Azad, Mitesh J Borad, Robin Kate Kelley
The Oncologist. 2022-10-01 - 54 citationsAdagrasib in Advanced Solid Tumors Harboring aMutation.Tanios S Bekaii-Saab, Rona Yaeger, Alexander I Spira, Meredith S Pelster, Joshua K Sabari
Journal of Clinical Oncology. 2023-09-01 - 158 citationsComparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.N. Jewel Samadder, Douglas L. Riegert-Johnson, Lisa A. Boardman, Deborah J. Rhodes, Myra J. Wick
JAMA Oncology. 2021-02-01
Journal Articles
- Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients with Hereditary Cancer SyndromeScott Okuno, Luke Mountjoy, Cameron S Thorpe, Edward D Esplin, Robert L Nussbaum, Alan H Bryce, Tanios S Bekaii-Saab, Aleksandar Sekulic, JAMA Oncology
- Systemic Therapy and Sequencing Options in Advanced Hepatocellular CarcinomaMohamad Bassam Sonbol, Amit Mahipal, Zhaohui Jin, Kabir Mody, Mitesh J Borad, Daniel H Ahn, Tanios Bekaii-Saab, JAMA Oncology
- Processes of Care in the Multidisciplinary Treatment of Gastric Cancer: Results of a RAND/UCLA Expert PanelBrar SS, Mahar AL, Helyer LK, Swallow C, Law C, Paszat L, Seevaratnam R, Cardoso R, McLeod R, Dixon M, Yohanathan L, Lourenco LG, Bocicariu A, Bekaii-Saab T, JAMA Surg, 11/13/2013
- Join now to see all
Lectures
- Phase III study of first-line (1L) pemigatinib (PEM) versus gemcitabine (GEM) plus cisplatin (CIS) for cholangiocarcinoma (CCA) with FGFR2 fusions or rearrangements.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Biomarker-Based Basket Trials: A New Model for Biliary Cancer Drug DevelopmentASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
- The POLO Trial Is Great, but Probably Not Practice-ChangingJune 2019
- The POLO Trial Is Great, but Probably Not Practice-ChangingJune 2019
Press Mentions
- Colon Cancer: Lowering Ammonia Levels Increases Tumor Treatment ResponseFebruary 8th, 2023
- ReDOS: Regorafenib Dose-Escalation Strategy in Refractory Advanced Colorectal CancerJuly 11th, 2019
- Dr. Bekaii-Saab on the APACT Trial in Pancreatic CancerOctober 3rd, 2019
- Join now to see all
Professional Memberships
- Member
Other Languages
- French, Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: